NAMS
NewAmsterdam Pharma Company N.V.
NASDAQ · Healthcare · Biotechnology · NL
$25.40
−1.74%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 110.73x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.81x
- Price / sales
- 426.38x
- Price / cash flow
- -21.16x
Enterprise value
- Enterprise value
- $2.4B
- EV / sales
- 337.38x
- EV / EBITDA
- -9.43x
- EV / EBIT
- -9.83x
- Market cap
- $3.0B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026